Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Citi
Argus Health
Colorcon
Harvard Business School
Daiichi Sankyo
Johnson and Johnson
Julphar
Cantor Fitzgerald
Queensland Health

Generated: December 11, 2017

Regulatory Exclusivity: NEW PRODUCT

Click here to include patents covering these drugs in this list

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Exclusivity Expiration Patented / Exclusive Use
Luitpold Pharms IncINJECTAFERferric carboxymaltoseINJECTABLE;INTRAVENOUS203565-001Jul 25, 2013RXYesYes► SubscribeNEW PRODUCT
LillyZYPREXA ZYDISolanzapineTABLET, ORALLY DISINTEGRATING;ORAL021086-004Apr 6, 2000ABRXYesNo► SubscribeNEW PATIENT POPULATION
LillyZYPREXA ZYDISolanzapineTABLET, ORALLY DISINTEGRATING;ORAL021086-001Apr 6, 2000ABRXYesYes► SubscribeNEW PATIENT POPULATION
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-003Dec 24, 2003ABRXYesYes► SubscribeNEW PATIENT POPULATION
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-001Apr 9, 2007ABRXYesNo► SubscribeNEW PATIENT POPULATION
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-001Dec 29, 1987AB1RXYesNo► SubscribeNEW PATIENT POPULATION
LillyZYPREXAolanzapineTABLET;ORAL020592-006Sep 9, 1997ABRXYesNo► SubscribeNEW PATIENT POPULATION
LillyZYPREXAolanzapineTABLET;ORAL020592-003Sep 30, 1996ABRXYesNo► SubscribeNEW PATIENT POPULATION
LillyZYPREXA ZYDISolanzapineTABLET, ORALLY DISINTEGRATING;ORAL021086-003Apr 6, 2000ABRXYesNo► SubscribeNEW PATIENT POPULATION
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-004Dec 24, 2003ABRXYesNo► SubscribeNEW PATIENT POPULATION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Chubb
Cantor Fitzgerald
Express Scripts
Medtronic
Healthtrust
Dow
Deloitte
McKinsey
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot